Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,892.00-0.12%ETH$2,284.26+0.69%GOLD$3,908.50+0.25%OIL$99.37-4.56%
Smart Investors Daily
SID Premium
AD

NASDAQ · ADMA

ADMA Biologics, Inc.

Healthcare · Biotechnology

$11.41

Down-$0.34 (-2.89%)

Updated Nov 2, 2026, 10:11 AM

SID Score

4.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.71B
P/E ratio
25.22
Dividend yield
0.00%
52-week range
$7.21 – $20.46
Volume
2.46M
Avg. volume
2.4M

Price performance · ADMA

ADMA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ADMA closed at $11.41 after 20 trading sessions, up 12.86% for the selected period.

Last close
$11.41
Period change
+12.86%
Period low
$10.11
Period high
$11.75
Daily close
View OHLC price history
ADMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$11.85$11.90$11.365$11.412.46M
Oct 29, 2026$11.37$11.77$11.342$11.752.74M
Oct 28, 2026$11.04$11.295$11.01$11.282.66M
Oct 27, 2026$11.02$11.19$10.90$11.172.22M
Oct 26, 2026$10.73$11.1185$10.70$11.0652.03M
Oct 23, 2026$10.88$10.905$10.57$10.681.74M
Oct 22, 2026$11.01$11.105$10.80$10.953.55M
Oct 21, 2026$11.17$11.275$10.925$11.012.01M
Oct 20, 2026$11.12$11.325$11.03$11.232.9M
Oct 19, 2026$10.66$11.14$10.66$11.072.87M
Oct 16, 2026$10.73$10.87$10.605$10.683.07M
Oct 15, 2026$10.60$10.91$10.48$10.732.77M
Oct 14, 2026$10.31$10.60$10.235$10.342.88M
Oct 13, 2026$10.19$10.355$10.025$10.313.76M
Oct 12, 2026$10.32$10.405$10.165$10.181.63M
Oct 9, 2026$10.32$10.505$10.25$10.362.83M
Oct 8, 2026$10.09$10.445$10.03$10.333.9M
Oct 7, 2026$10.15$10.32$10.07$10.143.05M
Oct 6, 2026$10.20$10.35$9.98$10.182.1M
Oct 5, 2026$9.63$10.19$9.62$10.113.51M

Latest ADMA news

The latest Smart Investors Daily articles mentioning ADMA.

Stock researchCompany · Overview

ADMA research

Overview

Company profile and research snapshot.

Company profile

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$16.00
Implied upside
—
Analysts
—
ADMA recent ratings
DateFirmRatingTarget
Jul 15, 2026MizuhoOutperform—
May 7, 2026Canaccord GenuityBuy—
May 7, 2026MizuhoOutperform—
Apr 21, 2026Canaccord GenuityBuy—
Apr 13, 2026MizuhoOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 31, 2026

GeneDx Holdings And 2 Other Top Healthcare Stocks

AI giants are planning up to US$828b in data center and chip spending this year, and that level of capital tied up in one corner of the market has many investors rethinking concentration risk. Capital that chases one story often overlooks steadier essentials like healthcare. This piece looks at three leading healthcare stocks from a curated screen of financially solid operators and explains why they may warrant a closer look now. The three stocks that follow are just a small sample, and the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By